Robert Rapaport
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robert Rapaport has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Kolevzon
Department of Psychiatry Icahn School of Medicine at Mount Sinai New York New York USA
3 shared publications - Julie Samuels
Albert Einstein College of Medicine, Children's Hospital at Montefiore Einstein, Bronx, New York
3 shared publications - Martin Oswald Savage
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
3 shared publications - Paige M. Siper
Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, USA
3 shared publications - Andrew Dauber
Division of Endocrinology, Children’s National Hospital, Washington, USA
2 shared publications Cassie Mintz
Division of Medical Genetics & Genomics, Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Wiley in American Journal of Medical Genetics Part A
ADNP ‐Related Helsmoortel–Van der Aa Syndrome: A Review of the Literature and Clinical Recommendations for Assessment and Monitoring
ADNP‐related Helsmoortel–Van der Aa syndrome (ADNP‐related HVDAS) is a single gene form of autism spectrum disorder (ASD) caused by pathogenic sequence variants in the activity‐dependent neuroprotective protein ( ADNP ) gene. In addition to ASD, ADNP‐related HVDAS is associated with a wide range of cognitive, behavioral, and physical health features that may lead to profound impairment in functioning and significantly impact quality of life for affected individuals, their families, and caregivers. However, because it remains rare, most clinicians are not familiar with the syndrome and lack knowledge to guide assessment and monitoring. The goals of this study are to (1) provide an updated systematic review of the clinical manifestations of ADNP‐related HVDAS, (2) establish recommendations for assessment and monitoring that can be used by caregivers when advocating for their children, and (3) be applied practically by clinicians caring for affected individuals. A literature review was conducted by searching PubMed, PsycInfo, and Embase databases using “ADNP”, “ADNP Syndrome,” and “Helsmoortel–Van der Aa Syndrome” through July 18, 2026. Articles were included if they reported on clinical manifestations of ADNP‐related HVDAS and were excluded if they did not describe at least one individual with the diagnosis. A total of 28 publications met inclusion criteria including case reports, case series, and small cohort studies; data were extracted for 209 cases and organized by clinical domain. A formal risk of bias assessment was not performed, and results were limited by the rarity of ADNP‐related HVDAS and thus small sample sizes, as well as variability in symptom reporting. Our updated review highlights the complex symptomatology of ADNP‐related HVDAS and the importance of early diagnosis, comprehensive evaluations, and individualized treatment planning.
- 17 September 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Open AccessADNP ‐Related Helsmoortel–Van der Aa Syndrome: A Review of the Literature and Clinical Recommendations for Assessment and Monitoring
ADNP‐related Helsmoortel–Van der Aa syndrome (ADNP‐related HVDAS) is a single gene form of autism spectrum disorder (ASD) caused by pathogenic sequence variants in the activity‐dependent neuroprotective protein ( ADNP ) gene. In addition to ASD, ADNP‐related HVDAS is associated with a wide range of cognitive, behavioral, and physical health features that may lead to profound impairment in functioning and significantly impact quality of life for affected individuals, their families, and caregivers. However, because it remains rare, most clinicians are not familiar with the syndrome and lack knowledge to guide assessment and monitoring. The goals of this study are to (1) provide an updated systematic review of the clinical manifestations of ADNP‐related HVDAS, (2) establish recommendations for assessment and monitoring that can be used by caregivers when advocating for their children, and (3) be applied practically by clinicians caring for affected individuals. A literature review was conducted by searching PubMed, PsycInfo, and Embase databases using “ADNP”, “ADNP Syndrome,” and “Helsmoortel–Van der Aa Syndrome” through July 18, 2026. Articles were included if they reported on clinical manifestations of ADNP‐related HVDAS and were excluded if they did not describe at least one individual with the diagnosis. A total of 28 publications met inclusion criteria including case reports, case series, and small cohort studies; data were extracted for 209 cases and organized by clinical domain. A formal risk of bias assessment was not performed, and results were limited by the rarity of ADNP‐related HVDAS and thus small sample sizes, as well as variability in symptom reporting. Our updated review highlights the complex symptomatology of ADNP‐related HVDAS and the importance of early diagnosis, comprehensive evaluations, and individualized treatment planning.
- Open Access
- 27 August 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1
International Consensus on the Diagnosis and Clinical Management of Idiopathic Short Stature: A Modified Delphi Method
Introduction: Idiopathic short stature (ISS) refers to children whose height falls substantially below the mean for sex and age relative to a reference population, despite the absence of an identifiable endocrine, genetic, syndromic, or systemic disorder. Clinical management remains challenging because no dedicated ICD-11 code exists and no universally accepted diagnostic criteria have been established. This has led to variability in how the condition is classified, inconsistency in access to testing, and uncertainty around eligibility for growth-promoting therapies. To address these inconsistencies and support broader global alignment in the recognition and management of ISS, an international consensus initiative was undertaken. Methods: A Steering Committee of 10 internationally recognized experts with extensive clinical and academic expertise in ISS supported the development of a structured modified Delphi process. An Expert Panel of 22 key opinion leaders participated in a three-round survey conducted between November 2025 and February 2026. Panelists evaluated draft statements related to ISS definition, diagnostic criteria, burden of disease, and decision to treat. Consensus thresholds were predefined at 70%, and statements were refined between rounds, as needed. Results: A total of 44 statements achieved consensus, with final agreement levels ranging from 77% to 100%. The statements establish a standardized clinical definition of ISS, propose evidence-based diagnostic criteria applicable across diverse healthcare settings, describe the impact of ISS on patients and caregivers, and suggest when to consider growth-promoting treatment for patients with ISS. For example, consensus was reached on the definition of ISS (a condition in which an individual has a height more than a standard deviation score of 2 below the mean for sex, age, and population, corresponding to below the 2.3 percentile, without identifiable underlying pathology) and on key elements of diagnostic evaluation (include the child's medical, developmental, and medication background, including prenatal and perinatal course, chronic illnesses or infections, and neurodevelopmental milestones, alongside family history and environmental exposures; perform a physical examination to identify clinical signs of underlying pathology, including assessment of body proportions, dysmorphic body features, head circumference, body mass index, and pubertal development). Key areas requiring future research were also highlighted. Conclusion: This international consensus offers the first globally derived, ISS-focused guidance developed using a formal Delphi methodology for identifying and managing children and adolescents with ISS. Adoption of these recommendations may reduce regional variability, improve diagnostic clarity, and ultimately enhance outcomes for individuals affected by ISS.
- 27 August 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1
Open AccessInternational Consensus on the Diagnosis and Clinical Management of Idiopathic Short Stature: A Modified Delphi Method
Introduction: Idiopathic short stature (ISS) refers to children whose height falls substantially below the mean for sex and age relative to a reference population, despite the absence of an identifiable endocrine, genetic, syndromic, or systemic disorder. Clinical management remains challenging because no dedicated ICD-11 code exists and no universally accepted diagnostic criteria have been established. This has led to variability in how the condition is classified, inconsistency in access to testing, and uncertainty around eligibility for growth-promoting therapies. To address these inconsistencies and support broader global alignment in the recognition and management of ISS, an international consensus initiative was undertaken. Methods: A Steering Committee of 10 internationally recognized experts with extensive clinical and academic expertise in ISS supported the development of a structured modified Delphi process. An Expert Panel of 22 key opinion leaders participated in a three-round survey conducted between November 2025 and February 2026. Panelists evaluated draft statements related to ISS definition, diagnostic criteria, burden of disease, and decision to treat. Consensus thresholds were predefined at 70%, and statements were refined between rounds, as needed. Results: A total of 44 statements achieved consensus, with final agreement levels ranging from 77% to 100%. The statements establish a standardized clinical definition of ISS, propose evidence-based diagnostic criteria applicable across diverse healthcare settings, describe the impact of ISS on patients and caregivers, and suggest when to consider growth-promoting treatment for patients with ISS. For example, consensus was reached on the definition of ISS (a condition in which an individual has a height more than a standard deviation score of 2 below the mean for sex, age, and population, corresponding to below the 2.3 percentile, without identifiable underlying pathology) and on key elements of diagnostic evaluation (include the child's medical, developmental, and medication background, including prenatal and perinatal course, chronic illnesses or infections, and neurodevelopmental milestones, alongside family history and environmental exposures; perform a physical examination to identify clinical signs of underlying pathology, including assessment of body proportions, dysmorphic body features, head circumference, body mass index, and pubertal development). Key areas requiring future research were also highlighted. Conclusion: This international consensus offers the first globally derived, ISS-focused guidance developed using a formal Delphi methodology for identifying and managing children and adolescents with ISS. Adoption of these recommendations may reduce regional variability, improve diagnostic clarity, and ultimately enhance outcomes for individuals affected by ISS.
- 23 July 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (2) , L5-L6
Comments on article discussing exome sequencing in children with short stature (79/85 characters)
- 23 July 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (2) , L5-L6
Comments on article discussing exome sequencing in children with short stature (79/85 characters)
- Open Access
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (6) , 1-2
Growth failure of unknown etiology
Dear Editor, I read with interest and pleasure your communication about “Healthy Short Stature” (). […] Growth failure of unknown etiology Dear Editor, I read with interest and pleasure your communication about “Healthy Short Stature” (). […] Growth failure of unknown etiology
- 1 January 2026
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 70 (6) , 1-2
Open AccessGrowth failure of unknown etiology
Dear Editor, I read with interest and pleasure your communication about “Healthy Short Stature” (). […] Growth failure of unknown etiology Dear Editor, I read with interest and pleasure your communication about “Healthy Short Stature” (). […] Growth failure of unknown etiology
- Open Access
- 31 August 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (4) , 201-206
Sex and racial/ethnic disparities in children presenting for short stature evaluation: in-depth analysis at a single center
Purpose: To assess disparities in children referred for short stature evaluation and to evaluate the effectiveness of physician interventions on referral rates.Methods: Retrospective chart review was conducted on children referred to a pediatric endocrinology center for short stature evaluation between 1/1/2022 and 12/31/2023. Interventions for participating physicians included an educational lecture and electronic medical record alert. Six-month pre- and postintervention referral rates for short stature from a general pediatrics practice were assessed.Results: There were 747 children (68% males) with a predominance of non-Hispanic White (NHW) children (64%). Females presented at a younger age (P<0.001), lower height (P<0.001), and a greater height deficit (P=0.002) than males. Hispanic children presented with greater height deficits than NHW and non-Hispanic Black (NHB) children (all P<0.05). In those with heights <-2 standard deviations (SDs) (n=192) from the mean, there were no significant sex differences; however, Hispanic children continued to have greater height deficit than NHW and NHB children (all P<0.02). There was no sex difference in those who underwent growth hormone stimulation testing (GHST); however, NHW children comprised the largest racial group. After implementing the interventions in the general pediatrics practice, short stature referral rates improved (15 of 118 referrals [13%] to 25 of 81 referrals [31%], P=0.002).Conclusion: Disparities in overall short stature referrals were less evident in the subset of children with heights <-2 SD from mean. There was no significant sex bias in GHST, but racial/ethnic disparities remained. Improvement in referring and evaluating females and children from minority groups is still crucial as they remain under referred.
- 31 August 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (4) , 201-206
Open AccessSex and racial/ethnic disparities in children presenting for short stature evaluation: in-depth analysis at a single center
Purpose: To assess disparities in children referred for short stature evaluation and to evaluate the effectiveness of physician interventions on referral rates.Methods: Retrospective chart review was conducted on children referred to a pediatric endocrinology center for short stature evaluation between 1/1/2022 and 12/31/2023. Interventions for participating physicians included an educational lecture and electronic medical record alert. Six-month pre- and postintervention referral rates for short stature from a general pediatrics practice were assessed.Results: There were 747 children (68% males) with a predominance of non-Hispanic White (NHW) children (64%). Females presented at a younger age (P<0.001), lower height (P<0.001), and a greater height deficit (P=0.002) than males. Hispanic children presented with greater height deficits than NHW and non-Hispanic Black (NHB) children (all P<0.05). In those with heights <-2 standard deviations (SDs) (n=192) from the mean, there were no significant sex differences; however, Hispanic children continued to have greater height deficit than NHW and NHB children (all P<0.02). There was no sex difference in those who underwent growth hormone stimulation testing (GHST); however, NHW children comprised the largest racial group. After implementing the interventions in the general pediatrics practice, short stature referral rates improved (15 of 118 referrals [13%] to 25 of 81 referrals [31%], P=0.002).Conclusion: Disparities in overall short stature referrals were less evident in the subset of children with heights <-2 SD from mean. There was no significant sex bias in GHST, but racial/ethnic disparities remained. Improvement in referring and evaluating females and children from minority groups is still crucial as they remain under referred.
- 3 April 2025
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 54 (2) , 251-260
Disparities in Pediatric Growth Evaluation, Diagnosis, and Treatment
- 3 April 2025
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 54 (2) , 251-260
Disparities in Pediatric Growth Evaluation, Diagnosis, and Treatment
- 3 December 2024
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 54 (1)
Advancing Obesity Medicine
- 3 December 2024
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 54 (1)
Advancing Obesity Medicine
- 22 June 2024
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 53 (3) , 13-14
Update on Endocrine Disorders During Pregnancy
- 22 June 2024
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 53 (3) , 13-14
Update on Endocrine Disorders During Pregnancy
- Open Access
- 1 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1398171
Evolving growth hormone deficiency: proof of concept
Introduction: We present the evolution of GHD in adolescent males with persistent growth failure, in whom the diagnosis was established after a second GH stimulation test (GST).Methods: We performed a retrospective chart review of children who presented for short stature (height less < 2SD for mean/mid-parental height) and/or growth failure (sustained growth velocity < 0 SD) to pediatric endocrinology at Mount Sinai Kravis Children’s Hospital, New York and who had 2 GSTs. Data collected from electronic medical records were analyzed using SPSS v28.0Results: Of 53 patients included, 42 were males. Average GH peak on initial GST was 15.48 ± 4.92 ng/ml, at 10.07 ± 2.65 years, mean height -1.68 ± 0.56SD(28% had <2SD), IGF-1 -1.00 ± 0.88SD. After 2.23 ± 1.22 years, at 12.04 ± 2.41years, height SDs decreased to -1.82 ± 0.63SD and IGF-1 was -1.08 ± 0.84SD. At repeat GST, average GH peak was 7.59 ± 2.12 ng/dL, with 36% ≤7 ng/dl and 32% in puberty. 12 males reached adult height of 0.08 ± 0.69 SD with a mean height gain of 1.83 ± 0.56SD(p<0.005), IGF-1 of -1.15 ± 0.81SD after 4.64 ± 1.4 years of GH.Conclusion: We offer evidence for Evolving Growth Hormone Deficiency (EGHD) through repeat GST in children with persistent growth slowdown, even with pubertal progression; emphasizing the need for careful longitudinal follow-up to make accurate diagnosis.
- 1 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1398171
Open AccessEvolving growth hormone deficiency: proof of concept
Introduction: We present the evolution of GHD in adolescent males with persistent growth failure, in whom the diagnosis was established after a second GH stimulation test (GST).Methods: We performed a retrospective chart review of children who presented for short stature (height less < 2SD for mean/mid-parental height) and/or growth failure (sustained growth velocity < 0 SD) to pediatric endocrinology at Mount Sinai Kravis Children’s Hospital, New York and who had 2 GSTs. Data collected from electronic medical records were analyzed using SPSS v28.0Results: Of 53 patients included, 42 were males. Average GH peak on initial GST was 15.48 ± 4.92 ng/ml, at 10.07 ± 2.65 years, mean height -1.68 ± 0.56SD(28% had <2SD), IGF-1 -1.00 ± 0.88SD. After 2.23 ± 1.22 years, at 12.04 ± 2.41years, height SDs decreased to -1.82 ± 0.63SD and IGF-1 was -1.08 ± 0.84SD. At repeat GST, average GH peak was 7.59 ± 2.12 ng/dL, with 36% ≤7 ng/dl and 32% in puberty. 12 males reached adult height of 0.08 ± 0.69 SD with a mean height gain of 1.83 ± 0.56SD(p<0.005), IGF-1 of -1.15 ± 0.81SD after 4.64 ± 1.4 years of GH.Conclusion: We offer evidence for Evolving Growth Hormone Deficiency (EGHD) through repeat GST in children with persistent growth slowdown, even with pubertal progression; emphasizing the need for careful longitudinal follow-up to make accurate diagnosis.
- 25 April 2024
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 53 (2)
Precocious and Delayed Puberty Revisited
- 25 April 2024
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 53 (2)
Precocious and Delayed Puberty Revisited